Clinical utility of cellular DNA measurements in prostate carcinoma

F. Schroder, B. Tribukait, A. Bocking, Ralph W deVere White, L. Koss, M. Lieber, B. Stenkvist, A. Zetterberg

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

At a WHO consensus conference on Early Diagnosis and Prognostic Parameters in Localized Prostate Cancer, a working group discussed the clinical utility of DNA measurements in stages T2 and T3 prostate carcinoma. Incidentally discovered prostate cancer of stage T1 was excluded. The members of the working group, representing various clinical and laboratory disciplines, discussed technical considerations of DNA measurements by flow and image analysis, pretreatment prediction of prognosis, and posttreatment clinical relevance. The group agreed to subdivide tumors into diploid, tetraploid and non-tetraploid aneuploid, expressing various degrees of aggressiveness and gave guidance for the definition of limits of these groups. The panel agreed that knowledge on DNA ploidy prior to treatment is of value in treatment decisions, particularly when surveillance is a treatment option. Aneuploid tumors can be expected to respond very poorly to either irradiation or endocrine therapy, and the presence of aneuploid tumor, either on pretreatment biopsies or in radical prostatectomy specimens, is an ominous sign. The identification of a group of patients with a uniformly poor prognosis should encourage medical oncologists and basic scientists to develop adequate treatment options for this particular group. The panel expressed a strong opinion that DNA ploidy should be uniformly studied in clinical trials, particularly in patients with localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)51-63
Number of pages13
JournalScandinavian Journal of Urology and Nephrology, Supplement
Issue number162
StatePublished - 1994
Externally publishedYes

Fingerprint

Prostate
Carcinoma
Aneuploidy
DNA
Prostatic Neoplasms
Ploidies
Therapeutics
Neoplasms
Social Identification
Tetraploidy
Prostatectomy
Diploidy
Early Diagnosis
Consensus
Clinical Trials
Biopsy

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Schroder, F., Tribukait, B., Bocking, A., deVere White, R. W., Koss, L., Lieber, M., ... Zetterberg, A. (1994). Clinical utility of cellular DNA measurements in prostate carcinoma. Scandinavian Journal of Urology and Nephrology, Supplement, (162), 51-63.

Clinical utility of cellular DNA measurements in prostate carcinoma. / Schroder, F.; Tribukait, B.; Bocking, A.; deVere White, Ralph W; Koss, L.; Lieber, M.; Stenkvist, B.; Zetterberg, A.

In: Scandinavian Journal of Urology and Nephrology, Supplement, No. 162, 1994, p. 51-63.

Research output: Contribution to journalArticle

Schroder, F, Tribukait, B, Bocking, A, deVere White, RW, Koss, L, Lieber, M, Stenkvist, B & Zetterberg, A 1994, 'Clinical utility of cellular DNA measurements in prostate carcinoma', Scandinavian Journal of Urology and Nephrology, Supplement, no. 162, pp. 51-63.
Schroder, F. ; Tribukait, B. ; Bocking, A. ; deVere White, Ralph W ; Koss, L. ; Lieber, M. ; Stenkvist, B. ; Zetterberg, A. / Clinical utility of cellular DNA measurements in prostate carcinoma. In: Scandinavian Journal of Urology and Nephrology, Supplement. 1994 ; No. 162. pp. 51-63.
@article{5c4bb637c6094cd28fbe030b878ea10c,
title = "Clinical utility of cellular DNA measurements in prostate carcinoma",
abstract = "At a WHO consensus conference on Early Diagnosis and Prognostic Parameters in Localized Prostate Cancer, a working group discussed the clinical utility of DNA measurements in stages T2 and T3 prostate carcinoma. Incidentally discovered prostate cancer of stage T1 was excluded. The members of the working group, representing various clinical and laboratory disciplines, discussed technical considerations of DNA measurements by flow and image analysis, pretreatment prediction of prognosis, and posttreatment clinical relevance. The group agreed to subdivide tumors into diploid, tetraploid and non-tetraploid aneuploid, expressing various degrees of aggressiveness and gave guidance for the definition of limits of these groups. The panel agreed that knowledge on DNA ploidy prior to treatment is of value in treatment decisions, particularly when surveillance is a treatment option. Aneuploid tumors can be expected to respond very poorly to either irradiation or endocrine therapy, and the presence of aneuploid tumor, either on pretreatment biopsies or in radical prostatectomy specimens, is an ominous sign. The identification of a group of patients with a uniformly poor prognosis should encourage medical oncologists and basic scientists to develop adequate treatment options for this particular group. The panel expressed a strong opinion that DNA ploidy should be uniformly studied in clinical trials, particularly in patients with localized prostate cancer.",
author = "F. Schroder and B. Tribukait and A. Bocking and {deVere White}, {Ralph W} and L. Koss and M. Lieber and B. Stenkvist and A. Zetterberg",
year = "1994",
language = "English (US)",
pages = "51--63",
journal = "Scandinavian Journal of Urology and Nephrology, Supplement",
issn = "0300-8886",
publisher = "Taylor and Francis Ltd.",
number = "162",

}

TY - JOUR

T1 - Clinical utility of cellular DNA measurements in prostate carcinoma

AU - Schroder, F.

AU - Tribukait, B.

AU - Bocking, A.

AU - deVere White, Ralph W

AU - Koss, L.

AU - Lieber, M.

AU - Stenkvist, B.

AU - Zetterberg, A.

PY - 1994

Y1 - 1994

N2 - At a WHO consensus conference on Early Diagnosis and Prognostic Parameters in Localized Prostate Cancer, a working group discussed the clinical utility of DNA measurements in stages T2 and T3 prostate carcinoma. Incidentally discovered prostate cancer of stage T1 was excluded. The members of the working group, representing various clinical and laboratory disciplines, discussed technical considerations of DNA measurements by flow and image analysis, pretreatment prediction of prognosis, and posttreatment clinical relevance. The group agreed to subdivide tumors into diploid, tetraploid and non-tetraploid aneuploid, expressing various degrees of aggressiveness and gave guidance for the definition of limits of these groups. The panel agreed that knowledge on DNA ploidy prior to treatment is of value in treatment decisions, particularly when surveillance is a treatment option. Aneuploid tumors can be expected to respond very poorly to either irradiation or endocrine therapy, and the presence of aneuploid tumor, either on pretreatment biopsies or in radical prostatectomy specimens, is an ominous sign. The identification of a group of patients with a uniformly poor prognosis should encourage medical oncologists and basic scientists to develop adequate treatment options for this particular group. The panel expressed a strong opinion that DNA ploidy should be uniformly studied in clinical trials, particularly in patients with localized prostate cancer.

AB - At a WHO consensus conference on Early Diagnosis and Prognostic Parameters in Localized Prostate Cancer, a working group discussed the clinical utility of DNA measurements in stages T2 and T3 prostate carcinoma. Incidentally discovered prostate cancer of stage T1 was excluded. The members of the working group, representing various clinical and laboratory disciplines, discussed technical considerations of DNA measurements by flow and image analysis, pretreatment prediction of prognosis, and posttreatment clinical relevance. The group agreed to subdivide tumors into diploid, tetraploid and non-tetraploid aneuploid, expressing various degrees of aggressiveness and gave guidance for the definition of limits of these groups. The panel agreed that knowledge on DNA ploidy prior to treatment is of value in treatment decisions, particularly when surveillance is a treatment option. Aneuploid tumors can be expected to respond very poorly to either irradiation or endocrine therapy, and the presence of aneuploid tumor, either on pretreatment biopsies or in radical prostatectomy specimens, is an ominous sign. The identification of a group of patients with a uniformly poor prognosis should encourage medical oncologists and basic scientists to develop adequate treatment options for this particular group. The panel expressed a strong opinion that DNA ploidy should be uniformly studied in clinical trials, particularly in patients with localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027968431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027968431&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027968431

SP - 51

EP - 63

JO - Scandinavian Journal of Urology and Nephrology, Supplement

JF - Scandinavian Journal of Urology and Nephrology, Supplement

SN - 0300-8886

IS - 162

ER -